Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg given for 24 days compared to a 21-day regimen.

被引：0
|
作者：
Ellman, H
Archer, DF
机构：
[1] CONRAD Clin Res Ctr, Norfolk, VA USA
[2] Warner Chilcott, Rockaway, NJ USA
来源：
FERTILITY AND STERILITY | 2005年 / 84卷
关键词：
D O I：
10.1016/j.fertnstert.2005.07.420
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：S169 / S170
页数：2
相关论文
共 36 条
  • [21] Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen
    Laszlo Hernadi
    Marr, Joachim
    Trummer, Dietmar
    De Leo, Vincenzo
    Petraglia, Felice
    CONTRACEPTION, 2009, 80 (01) : 18 - 24
  • [22] The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese users
    Creinin, Mitchell D.
    Angulo, Alicyoy
    Colli, Enrico
    Archer, David F.
    CONTRACEPTION, 2023, 128
  • [23] The Efficacy, Safety, and Tolerability of an Estrogen-Free Oral Contraceptive Drospirenone 4 mg (24/4-Day Regimen) in Obese Users
    Creinin, Mitchell D.
    Angulo, Alicyoy
    Colli, Enrico
    Archer, David F.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2024, 79 (04) : 210 - 211
  • [24] Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate
    Rible, Radhika D.
    Taylor, DeShawn
    Wilson, Melissa L.
    Stanczyk, Frank Z.
    Mishell, Daniel R., Jr.
    CONTRACEPTION, 2009, 79 (03) : 182 - 188
  • [25] Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen
    Brucker, Cosima
    Hedon, Bernard
    The, Hok Sien
    Hoeschen, Kornelia
    Binder, Natascha
    Christoph, Annette
    CONTRACEPTION, 2010, 81 (06) : 501 - 509
  • [26] A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinilestradiol 3 mg/20 mcg
    Mabrouk, Mohamed
    Solfrini, Serena
    Frasca, Clarissa
    Del Forno, Simona
    Montanari, Giulia
    Ferrini, Giulia
    Paradisi, Roberto
    Seracchioli, Renato
    GYNECOLOGICAL ENDOCRINOLOGY, 2012, 28 (06) : 451 - 454
  • [27] Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg
    Cibula, D
    Karck, U
    Weidenhammer, HG
    Kunz, J
    Alincic, S
    Marr, J
    CLINICAL DRUG INVESTIGATION, 2006, 26 (03) : 143 - 150
  • [28] Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20μg and Drospirenone 3mg
    D. Cibula
    U. Karck
    H. G. Weidenhammer
    J. Kunz
    S. Alincic
    J. Marr
    Clinical Drug Investigation, 2006, 26 : 143 - 150
  • [29] Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive
    Anttila, Leena
    Kunz, Michael
    Marr, Joachim
    CONTRACEPTION, 2009, 80 (05) : 445 - 451
  • [30] Follicular development during a 7-vs. 4-day hormone-free interval with an oral contraceptive containing 20 mcg of ethinyl estradiol and 1 mg norethindrone acetate
    Rible, R.
    Taylor, D.
    Tilley, I
    Segall-Gutierrez, P.
    Lewis, R.
    Mishell, D. R., Jr.
    CONTRACEPTION, 2008, 78 (02) : 173 - 173
1234